Y-mabs and nobelpharma announce exclusive license and distribution agreement for danyelza® (naxitamab-gqgk) in japan

New york, nov. 04, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, and nobelpharma co., ltd. today announced that they have entered into an exclusive license and distribution agreement for the development and commercialization in japan of danyelza for the treatment of patients with relapsed/refractory high-risk neuroblastoma and, upon agreement by the parties, potentially relapsed osteosarcoma.
YMAB Ratings Summary
YMAB Quant Ranking